Allakos Inc.

NASDAQ:ALLK

0.6 (USD) • At close September 13, 2024
Bedrijfsnaam Allakos Inc.
Symbool ALLK
Munteenheid USD
Prijs 0.605
Beurswaarde 53,719,133
Dividendpercentage 0%
52-weken bereik 0.56 - 3.41
Industrie Biotechnology
Sector Healthcare
CEO Dr. Robert Alexander Ph.D.
Website https://www.allakos.com

An error occurred while fetching data.

Over Allakos Inc.

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase

Vergelijkbare Aandelen

Meihua International Medical Technologies Co., Ltd. logo

Meihua International Medical Technologies Co., Ltd.

MHUA

1.07 USD

Sensus Healthcare, Inc. logo

Sensus Healthcare, Inc.

SRTS

6.09 USD

TFF Pharmaceuticals, Inc. logo

TFF Pharmaceuticals, Inc.

TFFP

2.21 USD

Vor Biopharma Inc. logo

Vor Biopharma Inc.

VOR

1.05 USD

Quipt Home Medical Corp. logo

Quipt Home Medical Corp.

QIPT

2.82 USD

Acumen Pharmaceuticals, Inc. logo

Acumen Pharmaceuticals, Inc.

ABOS

2.6 USD

scPharmaceuticals Inc. logo

scPharmaceuticals Inc.

SCPH

5.49 USD

NeuroPace, Inc. logo

NeuroPace, Inc.

NPCE

7.43 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)